



David P. Richman, M.D.

Clinical Interests	David P. Richman's professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor and muscle-specific kinase (MuSK), diseases of neuromuscular transmission, myasthenia gravis, anti-MuSK myasthenia, and Lambert-Eaton myasthenic syndrome, and the pathogenesis and control of autoimmune response in myasthenia gravis. Richman has coauthored an extensive list of publications and book chapters on neurological disease and related topics.
Title	Professor
Specialty	Neurology - Neuroimmunology, Myasthenia Gravis
Department	Neurology
Division	Neurology
Address/Phone	Lawrence J. Ellison Ambulatory Care Center, Neurology, 4860 Y St. Suite 0100 Sacramento, CA 95817 Phone: 916-734-3588
Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland, 1969 A.B., Princeton University, Princeton, New Jersey, 1965
Internships	Albert Einstein College of Medicine, New York City, New York, 1969-70
Residency	Albert Einstein College of Medicine, New York City, New York, 1970-71 Massachusetts General Hospital, Boston, Massachusetts, 1973-74
Fellowships	Harvard Medical School, Boston, Massachusetts, 1974-75 Massachusetts General Hospital, Boston, Massachusetts, 1974-76
Board Certifications	American Board of Psychiatry and Neurology, 1976
Professional Memberships	American Academy of Neurology American Association for the Advancement of Science American Association of Immunologists American Neurological Association National Myasthenia Gravis Foundation, Inc.



David P. Richman, M.D.

Select Recent Publications

- Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. *Arch Neurol*. 2012 Apr;69(4):453-60. Epub 2011 Dec 12.
- Richman DP. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. *Arch Neurol*. 2012 Apr;69(4):434-5. Epub 2011 Dec 12.
- Wong VS, Adamczyk P, Dahlin B, Richman DP, Wheelock V. Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions. *Cogn Behav Neurol*. 2011 Mar;24(1):40-2.
- Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis. *J Clin Neurol*. 2011 Dec;7(4):173-83. Epub 2011 Dec 29.
- Kim SS, Richman DP, Zamvil SS, Agius MA. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. *J Neurol Sci*. 2011 Jul 15;306(1-2):9-15. Epub 2011 May 6.
- Anderson JA, Ng JJ, Bowe C, McDonald C, Richman DP, Wollmann RL, Maselli RA. Variable phenotypes associated with mutations in DOK7. *Muscle Nerve*. 2008 Apr;37(4):448-56.
- Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. *Neurology*. 2008 Aug 5;71(6):400-6. Epub 2008 Apr 23.
- Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. *Neurology*. 2003 Dec 23;61(12):1652-61.
- Maselli RA, Kong D, Bowe C, McDonald C, Ellis W, Agius MA, Gomez CM, Richman DP, Wollmann RL. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. *Neurology* 57: 279-289, 2001.
- Roberts PF, Venuta F, Rendina E, De Giancomo T, Coloni GF, Follette DM, Richman DP, Benfield JR. Thymectomy in the treatment of ocular myasthenia gravis. *J. Thor. Cardiovasc. Surg.* 122: 562-8, 2001.
- Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, DuPont BL, Maselli RA. Antibody effector mechanisms in myasthenia gravis: the complement hypothesis *Annals of New York Academy of Science* 1998;841: 450-465
- Fairclough RH, Twaddle GM, Gudipati E, Lin MY, Richman DP. Differential surface accessibility of $\alpha(187-199)$ in the Torpedo acetylcholine receptor α subunits. *J. Mol. Biol.* 282:317-330, 1998.
- Fairclough, R.H., Twaddle, G.M., Gudipati, E., Richman, D.P., Burkwall, D.A., and Josephs R. Mapping the mAb 383C epitope to $\alpha(187-199)$ of the Torpedo acetylcholine receptor on the three dimensional model. *J. Mol. Biol.* 282:301-315, 1998.



David P. Richman, M.D.

© 2015 UC Regents